<DOC>
	<DOCNO>NCT01658878</DOCNO>
	<brief_summary>The first part study Dose Escalation Phase design establish safety nivolumab different dose level three cohort ( uninfected hepatocellular carcinoma ( HCC ) subject , hepatitis C virus ( HCV ) -infected HCC subject , hepatitis B virus ( HBV ) -infected subject ) . The second part study Expansion Phase design generate additional clinical data specify dos 3 cohort . A third cohort add study compare efficacy nivolumab sorafenib treatment Advanced HCC . A fourth cohort generate data safety efficacy combination nivolumab plus ipilimumab treatment Advanced HCC . In fifth cohort , additional clinical data generate Child-Pugh B subject .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness , Safety Tolerability Nivolumab Combination Nivolumab Plus Ipilimumab Patients With Advanced Liver Cancer</brief_title>
	<detailed_description>Study Classification : Pharmacokinetics/Pharmacodynamics</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects 18 year old ( men woman ) histologically confirm advanced hepatocellular carcinoma , eligible surgical and/or locoregional therapy ; progressive disease surgical /or locoregional therapy Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Dose Escalation Phase : ChildPugh score 7 point less . Cohort 5 : ChildPugh Class B ( B7B8 ) . For cohort ChildPugh score 6 point less History autoimmune disease Any prior current clinically significant ascites Any history hepatic encephalopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>